Literature DB >> 10502322

Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma.

J V Bovée1, A M Cleton-Jansen, N J Kuipers-Dijkshoorn, L J van den Broek, A H Taminiau, C J Cornelisse, P C Hogendoorn.   

Abstract

Chondrosarcomas are malignant cartilaginous tumors arising centrally in bone (central chondrosarcoma), or secondarily within the cartilaginous cap of a hereditary or sporadic exostosis (peripheral chondrosarcoma). Loss of heterozygosity (LOH) was studied by microsatellite analysis at the loci harboring the EXT genes (implicated in hereditary multiple exostoses), the EXT-like genes, and at 9p21, 13q14, 17p13, and chromosome 10. Nineteen of 20 peripheral chondrosarcomas showed LOH at all loci tested, while only 3 of 12 central chondrosarcomas exhibited LOH, restricted to 9p21, 10, 13q14, and 17p13. LOH at 9p21 did not appear to involve the CDKN2A gene, as assessed by SSCP analysis. DNA flow cytometry demonstrated a wide variation in the ploidy status in peripheral chondrosarcomas (DNA indexes, 0.56-2.01), whereas central chondrosarcomas were predominantly peridiploid. Near-haploidy found in peripheral chondrosarcomas could explain part of the high LOH percentages. Ki-67 immunohistochemistry suggested a higher proliferation rate in peripheral chondrosarcomas. Our results indicate that peripheral chondrosarcomas, arising secondarily to an exostosis, may obtain genetic alterations during malignant transformation, with subsequent genetic instability as demonstrated by a high percentage of LOH and a wide variation in ploidy status. In contrast, peridiploidy and a low percentage of LOH in central tumors suggest that a different oncogenic molecular mechanism may be operative. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502322

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  30 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency.

Authors:  Carlos E de Andrea; Ju-Fen Zhu; Huifeng Jin; Judith V M G Bovée; Kevin B Jones
Journal:  J Pathol       Date:  2015-03-03       Impact factor: 7.996

Review 3.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

Review 4.  Surgical treatment of sarcomas of the spine.

Authors:  Ali K Ozturk; Ziya L Gokaslan; Jean-Paul Wolinsky
Journal:  Curr Treat Options Oncol       Date:  2014-09

5.  No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas.

Authors:  Christianne M A Reijnders; Cathelijn J F Waaijer; Andrew Hamilton; Emilie P Buddingh; Sander P D Dijkstra; John Ham; Egbert Bakker; Karoly Szuhai; Marcel Karperien; Pancras C W Hogendoorn; Sally E Stringer; Judith V M G Bovée
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

6.  Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.

Authors:  Yvonne M Schrage; Liesbeth Hameetman; Karoly Szuhai; Anne-Marie Cleton-Jansen; Antonie H M Taminiau; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting.

Authors:  Liesbeth Hameetman; Petra Kok; Paul H C Eilers; Anne-Marie Cleton-Jansen; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2005-03-03       Impact factor: 4.064

8.  Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes.

Authors:  Cathelijn J F Waaijer; Carlos E de Andrea; Andrew Hamilton; Jolieke G van Oosterwijk; Sally E Stringer; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2012-08-18       Impact factor: 4.064

9.  Multiple osteochondromas: clinicopathological and genetic spectrum and suggestions for clinical management.

Authors:  Liesbeth Hameetman; Judith Vmg Bovée; Antonie Hm Taminiau; Herman M Kroon; Pancras Cw Hogendoorn
Journal:  Hered Cancer Clin Pract       Date:  2004-11-15       Impact factor: 2.857

Review 10.  Molecular pathology of sarcomas: concepts and clinical implications.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-09-29       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.